If you've been told hormone therapy "causes breast cancer" or "isn't worth the risk," there's a good chance the source — directly or indirectly — is a single study from 2002. That study shaped a generation of medical practice. And much of what got reported about it was either wrong or misapplied.
Twenty years of follow-up data and reanalysis has shifted the picture significantly. Hormone therapy is not the right choice for everyone, but it's a reasonable, evidence-based option for many people. Here's what we actually know.
A Quick History of the WHI
The Women's Health Initiative was a large randomized trial that, in 2002, published an interim analysis showing increased rates of breast cancer, heart disease, stroke, and blood clots among women taking combined estrogen-plus-progestin hormone therapy [1].
The study made global headlines. Prescriptions for hormone therapy dropped roughly 70% within a few years. A generation of providers stopped offering it. A generation of patients stopped asking.
Here's what got lost in the headlines:
The average age of participants was 63. Most were more than 10 years past menopause when they started hormone therapy. That's not when most people seek HRT — most are in their late 40s or early 50s, in or just past the menopausal transition.
The absolute risk increases were small. The relative-risk numbers in the press release looked alarming. The actual additional risk per 10,000 women per year was much smaller than headlines suggested.
The progestin used (medroxyprogesterone acetate) is not what most providers prescribe today. Newer forms of progesterone, including micronized progesterone and the levonorgestrel IUD, have different risk profiles.
The estrogen-only arm of the study found a decreased risk of breast cancer. This part rarely made the headlines.
The Timing Hypothesis
Subsequent analysis of WHI and other studies pointed to what's now called the "timing hypothesis": when hormone therapy is started matters enormously [2,3].
For women who start hormone therapy within 10 years of menopause and before age 60, the data show:
- Reduced risk of cardiovascular disease (not increased)
- Reduced all-cause mortality
- Reduced fracture risk
- Effective treatment of vasomotor symptoms (hot flashes, night sweats)
- Treatment of genitourinary symptoms
For women who start hormone therapy more than 10 years after menopause or after 60, the risk-benefit calculation is different — and starting at that point isn't usually recommended for prevention purposes.
The WHI participants, on average, were in this second group. The study didn't disprove that HRT helps symptomatic perimenopausal and menopausal women. It showed that starting HRT at 65 to prevent disease isn't a good idea.
What Modern HRT Looks Like
The HRT we offer today isn't the HRT in the WHI study:
Estrogen — usually estradiol, often delivered transdermally (patches, gels, sprays). Transdermal estrogen avoids first-pass metabolism through the liver, which lowers the risk of blood clots compared to oral estrogen.
Progestogen — required for anyone with a uterus to protect the uterine lining. Options include micronized progesterone (Prometrium), the levonorgestrel IUD (Mirena), or other formulations. Different options have different side-effect profiles.
Vaginal estrogen — for genitourinary symptoms specifically. Systemic absorption is minimal. The risk profile is very different from systemic HRT, and it's appropriate for many people who can't use systemic hormones.
Who's a Reasonable Candidate
The criteria below align with current guidance from the North American Menopause Society and ACOG [4,5]. You're likely a candidate for hormone therapy if:
- You're under 60 or within 10 years of menopause
- You have bothersome symptoms (hot flashes, night sweats, sleep disruption, mood, vaginal dryness)
- You don't have a current or recent history of breast cancer
- You don't have a history of estrogen-dependent cancer
- You don't have a recent or active blood clot or stroke
- You don't have unexplained vaginal bleeding (we'd evaluate first)
- You don't have active liver disease
Risk factors that need a real conversation, not an automatic no:
- Family history of breast cancer
- History of migraines (especially with aura)
- Smoking
- High blood pressure
- Personal or family history of clotting disorders
These are conversations, not disqualifications. Transdermal estrogen, in particular, has a much lower clot risk than oral estrogen and changes the calculus for many of these.
What About Bioidentical Hormones?
Quick clarification because this comes up constantly:
FDA-approved bioidentical hormones exist and are commonly prescribed. Estradiol patches, gels, and oral tablets, plus micronized progesterone — these are bioidentical (chemically identical to what your body makes) and are regulated, standardized, and covered by most insurance.
Compounded "bioidentical" hormones from compounding pharmacies are different. They're not FDA-regulated, doses can vary batch-to-batch, and there's less safety data. They're often marketed aggressively but offer no proven advantage over FDA-approved bioidenticals for most patients.
We prescribe FDA-approved bioidentical hormones. Compounded products have a narrow set of legitimate uses, but for most patients they're not necessary.
How We Approach It
A menopause consultation with us looks like this:
- We talk through your symptoms, your history, and what's bothering you most
- We review risk factors honestly — not as gatekeeping but as part of an actual decision
- We discuss the options, including non-hormonal alternatives
- You decide. We don't push HRT and we don't refuse it without a real reason
- If you start, we follow up to adjust dose, formulation, or delivery method based on how you feel
Insurance Coverage
Most insurance plans we accept (BCBS, Anthem, Cigna, UHC, Aetna, CareFirst) cover FDA-approved hormone therapy with standard prescription drug benefits. Compounded products are usually not covered. We have a separate post on insurance coverage for menopause care.
Ready to Talk
Book a menopause consultation online, available in-office or via telehealth. Or send us a message if you have questions first.
You may also want to read about perimenopause symptoms that get dismissed or what to do about painful sex and dryness.
References
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
- Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
- Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med. 2006;21(4):363-366.
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
- ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216.